Abiomed is dedicated to finding ways to treat heart failure so that patients and physicians with have the most advanced, most successful, and most beneficial technology available. Our products focus on acute heart failure, with products across the continuum of care to support physician and patient needs.

The IMPELLA® Circulatory Support System consists of minimally invasive catheter pumps that can support the heart with up to 5 liters of blood per minute. The pumps can be implanted percutaneously, via a cut-down, or in the OR and provide support for one or both ventricles.

The iPulse™ Circulatory Support System, recently launched in Europe, provides temporary support for one or both sides of the natural heart in circumstances where the heart has failed but has the potential to recover.

Previously, Abiomed Europe sold both the AB5000™ and the BVS® 5000 Circulatory Support Systems. The BVS is the most widely used advanced cardiac assist system in the world, installed in more than 700 leading medical centers worldwide. Now, Abiomed Europe offers the iPulse™ Circulatory Support System, ABIOMED's most advanced Circulatory Support system, designed to provide improved patient mobility and for recovering the native function of the heart. It can drive an IAB (intra-aortic balloon), AB5000™ Ventricles or BVS® 5000 Blood Pumps.

The AbioCor is the world's first completely self-contained replacement heart. A product of three decades of research, development and testing, the AbioCor is central to ABIOMED's mission to make real the day when heart failure need not mean the end of life or the ability to enjoy life. Designed to fully sustain the body's circulatory system, the AbioCor is intended for end-stage heart failure patients whose other treatment options have been exhausted.

In 2001, ABIOMED made history when Mr. Robert Tools, a 58-year-old telephone company employee and teacher suffering from end stage heart failure was successfully implanted with the first AbioCor. The initial clinical trial is continuing with the aim of gaining approval to market the AbioCor to support patients with irreversible end-stage heart failure. The company also recently received FDA commercial approval for the AbioCor under a Humanitarian Device Exemption.

ABIOMED is also working on the next generation implantable replacement heart, the AbioCor II. Incorporating technology both from ABIOMED and Penn State, the AbioCor II is smaller and is being designed with a goal of five year reliability.

NOTE:

The AbioCor is NOT CE marked and is NOT available in Europe at this time.